Molecular testing is crucial for precision oncology in AML and MDS, but barriers hinder its routine integration. The study analyzed genomic data from 2018 to 2023, focusing on testing rates, types, ...

Sevabertinib, targeting HER2 and EGFR mutations, received FDA breakthrough designation for HER2+ NSCLC, showing a 59% overall response rate in treatment-naive patients. Discover the latest ...

Autonomix's targeted ablation therapy improved symptoms, functionality, and quality of life in severe pancreatic cancer patients, especially those with stage 4 disease. Rapid pain relief and durable ...

The findings show that prolonged targeted therapy in patients with head and neck cancer can heighten tumor alertness, ...

A new targeted alpha therapy is showing promise for patients whose thyroid cancer no longer responds to radioactive iodine, the standard beta-emitting treatment. In a first-in-human study, ...

Targeted therapies are cancer medications that work more selectively than standard chemotherapy medications. They do this by targeting specific molecules or genetic changes in cancer cells in order to ...

CAR T-cell therapy is being adapted for clear cell renal cell carcinoma, targeting CAIX and CD70 to improve efficacy and safety. Early trials like COBALT-RCC and TRAVERSE show promising disease ...